{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:11:22Z","timestamp":1790845882988,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.thromres.2015.03.032","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T06:09:57Z","timestamp":1428732597000},"page":"1186-1190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters"],"prefix":"10.1016","volume":"135","author":[{"given":"Armando","family":"Tripodi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lidia","family":"Padovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantarangkul","family":"Veena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Scalambrino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Testa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2015.03.032_bb0005","doi-asserted-by":"crossref","DOI":"10.1515\/cclm-2014-0307","article-title":"Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate","author":"Dinkelaar","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.thromres.2015.03.032_bb0010","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1160\/TH13-07-0607","article-title":"Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban","volume":"111","author":"Herrmann","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3810\/hp.2013.02.1009","article-title":"Inhibitory effect of apixaban compared with rivaroxaban and dabigatran on thrombin generation assay","volume":"41","author":"Wong","year":"2013","journal-title":"Hosp Pract (1995)"},{"key":"10.1016\/j.thromres.2015.03.032_bb0020","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s11239-012-0857-9","article-title":"Dabigatran attenuates thrombin generation to a lesser extent than warfarin: could this explain their differential effects on intracranial hemorrhage and myocardial infarction?","volume":"35","author":"Dale","year":"2013","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.thromres.2015.03.032_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11239-011-0654-x","article-title":"Effects of dabigatran in vitro on thrombin biomarkers by Calibrated Automated Thrombography in patients after ischemic stroke","volume":"33","author":"Serebruany","year":"2012","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.thromres.2015.03.032_bb0030","doi-asserted-by":"crossref","first-page":"e78696","DOI":"10.1371\/journal.pone.0078696","article-title":"Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood","volume":"8","author":"Escolar","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2015.03.032_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/jth.12830","article-title":"Multimodal assessment of non-specific hemostatic agents for apixaban reversal","author":"Martin","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0040","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2015.03.032_bb0045","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thromres.2015.03.032_bb0050","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1160\/TH13-06-0470","article-title":"Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study","volume":"111","author":"Gouin-Thibault","year":"2014","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0055","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1160\/TH12-12-0898","article-title":"Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide","volume":"110","author":"Douxfils","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0060","doi-asserted-by":"crossref","DOI":"10.1111\/jth.12649","article-title":"Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti-FXa assays","volume":"12","author":"Hillarp","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000071636","article-title":"Calibrated automated thrombin generation measurement in clotting plasma","volume":"33","author":"Hemker","year":"2003","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.thromres.2015.03.032_bb0070","first-page":"547","article-title":"Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability","volume":"88","author":"Chantarangkul","year":"2003","journal-title":"Haematologica"},{"key":"10.1016\/j.thromres.2015.03.032_bb0075","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/bcp.12106","article-title":"Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects","volume":"76","author":"Frost","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.thromres.2015.03.032_bb0080","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1538-7836.2011.04358.x","article-title":"Thrombin generation assay using factor IXa as a trigger to quantify accurately factor VIII levels in haemophilia A","volume":"9","author":"Ninivaggi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0085","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1160\/TH09-03-0176","article-title":"Assessment of laboratory assays to measure rivaroxaban\u2013an oral, direct factor Xa inhibitor","volume":"103","author":"Samama","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0090","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1538-7836.2010.04106.x","article-title":"The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study","volume":"9","author":"Tripodi","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0095","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1111\/j.1538-7836.2004.00964.x","article-title":"Clinical measurement of thrombin generation by calibrated automated thrombography requires contact factor inhibition","volume":"2","author":"Luddington","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0100","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1160\/TH08-10-0670","article-title":"Monitoring thrombin generation: is addition of corn trypsin inhibitor needed?","volume":"101","author":"Spronk","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/jth.12769","article-title":"Failure of corn trypsin inhibitor to affect the thrombin generation assay in plasma from severe haemophiliacs: comment","volume":"13","author":"Tripodi","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2015.03.032_bb0110","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1111\/j.1538-7836.2012.04627.x","article-title":"Comparison of thrombin generation for paired-platelet-rich plasma collected with and without corn trypsin inhibitor from hemophiliacs treated with factor-VIII inhibitor bypassing agents","volume":"10","author":"Tripodi","year":"2012","journal-title":"J Thromb Haemost"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384815001541?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384815001541?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T05:03:49Z","timestamp":1566536629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384815001541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0049384815001541"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2015.03.032","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How the Direct Oral Anticoagulant Apixaban Affects Thrombin Generation Parameters","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2015.03.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}